BridgeBio Pharma

Update in progress

BBIO (NasdaqGS)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

BridgeBio Pharma discovers and develops medicines for genetic diseases. Its programs include Attruby, a TTR stabilizer for ATTR-CM; Fosdenopterin (NULIBRY) for molybdenum cofactor deficiency; low-dose infigratinib for achondroplasia and hypochondroplasia; Encaleret for Autosomal Dominant Hypocalcemia Type 1 and Chronic Hypoparathyroidism; BBP-418 for LGMD2I; and BBP-812 AAV gene therapy for Canavan disease. It partners with Bayer, Alexion, Stanford, and Novartis. Founded 2015, Palo Alto.

Company score

Sentiment: 0.93; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.01; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.94; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.20; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.32; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.63; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive